About Us
LCT is an Australasian biotechnology company improving the wellbeing of people with serious diseases by discovering, developing and commercialising novel treatments for debilitating conditions.
Product candidates include:
- NTCELL, an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells targeting Parkinson’s disease.
LCT is listed on the Australian (ASX: LCT) and US (OTCQB: LVCLY) stock exchanges and is incorporated in Australia, with operations based in Australia and New Zealand.
